Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer

BackgroundLenvatinib combined with anti-PD-1 antibodies and systemic chemotherapy has demonstrated a relatively high antitumor activity for intrahepatic cholangiocarcinoma in phase 2 clinical trials. However, its efficacy and safety in advanced biliary tract cancer (BTC) has not been reported in a r...

Full description

Bibliographic Details
Main Authors: Chengpei Zhu, Jingnan Xue, Yunchao Wang, Shanshan Wang, Nan Zhang, Yanyu Wang, Longhao Zhang, Xu Yang, Junyu Long, Xiaobo Yang, Xinting Sang, Haitao Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
advanced biliary tract cancer
lenvatinib
PD-1 inhibitor
PD-L1 inhibitor
Gemox chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1109292/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1109292/full

Similar Items